{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:59:51Z","timestamp":1791388791160,"version":"4.3.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,21]]},"DOI":"10.7759\/cureus.35276","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T23:11:45Z","timestamp":1677021105000},"source":"Crossref","is-referenced-by-count":7,"title":["A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Jonathan","family":"Salangsang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Sapkota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Kharel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci7100100","article-title":"Targeted therapies and immunotherapies in the treatment of esophageal cancers","volume":"7","author":"Barsouk A","year":"2019","unstructured":"Barsouk A, Rawla P, Hadjinicolaou AV, Aluru JS, Barsouk A. Targeted therapies and immunotherapies in the treatment of esophageal cancers. Med Sci (Basel). 2019, 7:10.3390\/medsci7100100","journal-title":"Med Sci (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0221","article-title":"FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1","volume":"24","author":"Fashoyin-Aje L","year":"2019","unstructured":"Fashoyin-Aje L, Donoghue M, Chen H, et al.. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist. 2019, 24:103-9. 10.1634\/theoncologist.2018-0221","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs CS","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, et al.. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018, 4:e180013. 10.1001\/jamaoncol.2018.0013","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli AM","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, et al.. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018, 67:1471-80. 10.2337\/dbi18-0002","journal-title":"Diabetes"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1085w","article-title":"Autoimmune diabetes associated with pembrolizumab: a review of published case reports","volume":"9","author":"Cheema A","year":"2018","unstructured":"Cheema A, Makadia B, Karwadia T, Bajwa R, Hossain M. Autoimmune diabetes associated with pembrolizumab: a review of published case reports. World J Oncol. 2018, 9:1-4. 10.14740\/wjon1085w","journal-title":"World J Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-22-9","article-title":"Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1\/PD-L1 immunotherapy","volume":"5","author":"Bevins NJ","year":"2022","unstructured":"Bevins NJ, Okamura R, Montesion M, Adashek JJ, Goodman AM, Kurzrock R. Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1\/PD-L1 immunotherapy. J Immunother Precis Oncol. 2022, 5:90-7. 10.36401\/JIPO-22-9","journal-title":"J Immunother Precis Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00014","article-title":"Immune checkpoint inhibitor-induced diabetic ketoacidosis: a report of four cases and literature review","volume":"11","author":"Hong AR","year":"2020","unstructured":"Hong AR, Yoon JH, Kim HK, Kang HC. Immune checkpoint inhibitor-induced diabetic ketoacidosis: a report of four cases and literature review. Front Endocrinol (Lausanne). 2020, 11:14. 10.3389\/fendo.2020.00014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2017.32.1.23","article-title":"Acute hyperglycemia associated with anti-cancer medication","volume":"32","author":"Hwangbo Y","year":"2017","unstructured":"Hwangbo Y, Lee EK. Acute hyperglycemia associated with anti-cancer medication. Endocrinol Metab (Seoul). 2017, 32:23-9. 10.3803\/EnM.2017.32.1.23","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref9","unstructured":"Immune checkpoint inhibitors and thyroid dysfunction. a case from the endocrine teaching clinics - Mayo Clinic. (2021). Accessed: January 31, 2023: https:\/\/www.mayoclinic.org\/medical-professionals\/endocrinology\/news\/immune-checkpoint-inhibitors-and-thyroid-dysfunct...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0098","article-title":"Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism","volume":"2019","author":"Patel S","year":"2019","unstructured":"Patel S, Chin V, Greenfield JR. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530\/EDM-19-0098","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-18-0153","article-title":"A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma","volume":"2019","author":"Hakami OA","year":"2019","unstructured":"Hakami OA, Ioana J, Ahmad S, Tun TK, Sreenan S, McDermott JH. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530\/EDM-18-0153","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals M","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, et al.. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020, 6:38. 10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk HK","year":"2019","unstructured":"Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019, 36:1075-81. 10.1111\/dme.14050","journal-title":"Diabet Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-012-0098-3","article-title":"Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa A","year":"2012","unstructured":"Imagawa A, Hanafusa T, Awata T, et al.. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). Diabetol Int. 2012, 3:179-83. 10.1007\/s13340-012-0098-3","journal-title":"Diabetol Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang LS","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019, 40:17-65. 10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-245846","article-title":"Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab","volume":"15","author":"Zand Irani A","year":"2022","unstructured":"Zand Irani A, Almuwais A, Gibbons H. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab. BMJ Case Rep. 2022, 15:10.1136\/bcr-2021-245846","journal-title":"BMJ Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis DA","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, et al.. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017, 102:2770-80. 10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer PC","year":"2018","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG, et al.. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018, 28:1243-51. 10.1089\/thy.2018.0116","journal-title":"Thyroid"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JB","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18983","article-title":"Pembrolizumab-induced diabetic ketoacidosis: a review of critical care case","volume":"13","author":"Sankar K","year":"2021","unstructured":"Sankar K, Macfarlane M, Cooper O, Falk J. Pembrolizumab-induced diabetic ketoacidosis: a review of critical care case. Cureus. 2021, 13:e18983. 10.7759\/cureus.18983","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/140072-a-case-of-pembrolizumab-induced-diabetic-ketoacidosis-and-hyperthyroidism-in-a-patient-with-recurrent-esophageal-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:29Z","timestamp":1707508289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/140072-a-case-of-pembrolizumab-induced-diabetic-ketoacidosis-and-hyperthyroidism-in-a-patient-with-recurrent-esophageal-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.35276","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,21]]}}}